- Nov 13, 2009
- 3,322
- 116
- 0
Still holding... thinking I'll ride it out and see if the buyout happens. Always a gambler...
Stock Market Thread - ALL COMBINED
- Thread starter vinnie
- Start date
ACTC Conference call after the close tomorrow. I won't be available to listen, maybe somebody else will :shrug:
There's a long shot chance we get some news from the trials that are gong on.
Earnings Call
Good luck, fellas :0008
There's a long shot chance we get some news from the trials that are gong on.
Earnings Call
Good luck, fellas :0008
jesus f*** chr***
what a day to release a earnings report !!
Advanced Cell Technology Announces 2011 Second Quarter Results
Company Exits Quarter with $16.1 million in cash
MARBOROUGH, Mass., Aug 08, 2011 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT", OTCBB: ACTC)(the "Company"), a leader in the field of regenerative medicine, announced today second quarter financial results for the period ended June 30, 2011. ACT had revenue of approximately $0.2 million for the 2011 second quarter, compared to revenue of $0.2 million in the year earlier period. Revenue was generated through license fees and royalty payments. Research and Development expenses for the three months ended June 30, 2011 and 2010 were $1,532,271 and $1,484,141, respectively
The Company reported a loss from operations of $(3.6) million compared to a loss from operations of $(1.1) million in the 2010 second quarter. ACT reported a net loss of $(4.8) million or $(0.00) per share, compared to net income in the same period of 2010 of $2.9 million, or $(0.00) per share. The change in net income (loss) in each period is primarily related to the changes in the fair value of the derivative liabilities, which were largely a result of an increase in the Company's share price.
Net cash used in operations for the 2011 second quarter was $3.2 million, compared to net cash used in operations of $1.8 million in the same period in 2010. The net cash used in operations increased as a result of the Company preparing for, and commencing, its clinical trials. The Company ended the 2011 second quarter with cash and cash equivalents of $16.1 million, compared to $13.7 million as of March 31, 2011 after drawing down approximately $4 million from its available equity commitment.
"We are excited to have commenced our landmark Phase I/II trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD)," said Gary Rabin, interim Chairman and CEO of ACT. "Entering the trials with a strong balance sheet, ACT is well positioned to negotiate strategic partnerships and licensing agreements as we move these exciting programs through the clinic."
what a day to release a earnings report !!
Advanced Cell Technology Announces 2011 Second Quarter Results
Company Exits Quarter with $16.1 million in cash
MARBOROUGH, Mass., Aug 08, 2011 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. ("ACT", OTCBB: ACTC)(the "Company"), a leader in the field of regenerative medicine, announced today second quarter financial results for the period ended June 30, 2011. ACT had revenue of approximately $0.2 million for the 2011 second quarter, compared to revenue of $0.2 million in the year earlier period. Revenue was generated through license fees and royalty payments. Research and Development expenses for the three months ended June 30, 2011 and 2010 were $1,532,271 and $1,484,141, respectively
The Company reported a loss from operations of $(3.6) million compared to a loss from operations of $(1.1) million in the 2010 second quarter. ACT reported a net loss of $(4.8) million or $(0.00) per share, compared to net income in the same period of 2010 of $2.9 million, or $(0.00) per share. The change in net income (loss) in each period is primarily related to the changes in the fair value of the derivative liabilities, which were largely a result of an increase in the Company's share price.
Net cash used in operations for the 2011 second quarter was $3.2 million, compared to net cash used in operations of $1.8 million in the same period in 2010. The net cash used in operations increased as a result of the Company preparing for, and commencing, its clinical trials. The Company ended the 2011 second quarter with cash and cash equivalents of $16.1 million, compared to $13.7 million as of March 31, 2011 after drawing down approximately $4 million from its available equity commitment.
"We are excited to have commenced our landmark Phase I/II trials for Stargardt's Macular Dystrophy (SMD) and Dry Age-Related Macular Degeneration (Dry AMD)," said Gary Rabin, interim Chairman and CEO of ACT. "Entering the trials with a strong balance sheet, ACT is well positioned to negotiate strategic partnerships and licensing agreements as we move these exciting programs through the clinic."
<iframe width="425" height="349" src="http://www.youtube.com/embed/sNOX7RbpTe0" frameborder="0" allowfullscreen></iframe>
:shrug:
Nothing wrong with that report. They aren't making money.....YET. Everybody knows that. Plus, they didn't know the market was going to take a shit when they made today ER day :shrug:
I'm hearing the CC went very well and I'm not worried about this stock in the least.
Patience :0074
Just glad I pulled out in June with everything else. I'll be ready for some good buys when things turn back around. I can wait for better days
opcorn2
Futures just turned green :shrug:
Now that all the retail players lost their asses and had to get out re margin calls, they'll pump this thing right back up.
I might not know what I'm talking about but I do know they are a bunch of crooked pricks and it's not on the level.
My only regret is not shorting the S&P back in early June like I said I was going to do. :facepalm:
I could have become an MJ millionaire :142smilie
Now that all the retail players lost their asses and had to get out re margin calls, they'll pump this thing right back up.
I might not know what I'm talking about but I do know they are a bunch of crooked pricks and it's not on the level.
My only regret is not shorting the S&P back in early June like I said I was going to do. :facepalm:
I could have become an MJ millionaire :142smilie
- Nov 13, 2009
- 3,322
- 116
- 0
- Nov 13, 2009
- 3,322
- 116
- 0
